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S
moking is considered an important
“risk factor” for arterial hyperten-
sion and diabetes management, ac-
cording to, respectively, the current
guidelines of the European Society of Hy-
pertension and the European Society of
Cardiologyonthemanagementofarterial
hypertension (1) and the guidelines on
diabetes of the European Society of Car-
diology and the European Association for
the Study of Diabetes (2). The aim of the
current article is to further evaluate the
effect of smoking on mortality and cause-
speciﬁc cardiovascular events in hyper-
tension and in diabetes and to assess
whether there is a signiﬁcant interaction
between the effects of smoking and
diabetes.
SMOKING AND
HYPERTENSION— To assess the
effect of smoking on mortality and cause-
speciﬁccardiovascularevents,andthein-
teraction between smoking and diabetes,
we analyzed a database of 3,468 hyper-
tensive patients without major cardiovas-
cular disease at baseline and with
prospective follow-up for morbidity and
mortality (3). The database consists of in-
dividual data of hypertensive patients
from four prospective studies performed
in Europe (4–7). Age of the subjects av-
eraged 61  13 years (mean  SD), 45%
were men, and 61% were under antihy-
pertensive treatment at baseline. Ofﬁce
blood pressure averaged 159.0  19.9/
91.011.7mmHgand24-hambulatory
bloodpressure138.116.4/82.311.0
mmHg. Current smoking and diabetes
were coded as yes or no at the baseline
examination; 13.7% of the patients
smoked and 8.4% had diabetes. We used
Cox proportional hazards regression
analysis to assess the prognostic signiﬁ-
cance of smoking, with stratiﬁcation for
study and adjustment for age, sex, diabe-
tes, total cholesterol, 24-h systolic blood
pressure,antihypertensivetreatment,and
BMI. The average 24-h blood pressure
wasusedbecauseitspredictivepowerhas
beenshowntobesuperiortothatofofﬁce
blood pressure (3). Median follow-up
time was 6.57 years (range 0.08–13.1)
and total follow-up time amounted to
23,164 patient-years. Table 1 shows the
results for all-cause mortality, noncardio-
vascular mortality, and cardiovascular
mortality, which includes all fatal cardio-
vasculareventsandsuddendeath.Table2
shows the results for fatal and nonfatal
coronary heart disease, congestive heart
failure, and stroke. Coronary heart dis-
ease included sudden death and fatal and
nonfatal myocardial infarction. Conges-
tive heart failure required the presence of
three disorders: symptoms such as dys-
pnoea, clinical signs such as ankle edema
or crepitations, and the necessity of treat-
ment. Stroke was deﬁned as a neurologi-
cal deﬁcit with symptoms continuing for
24 h or leading to death with no appar-
ent cause other than vascular; transient
ischemic attack was not an end point. As
shown in Tables 1 and 2, smoking was a
signiﬁcantandindependentriskfactorfor
all-cause, cardiovascular, and noncardio-
vascular mortality and for fatal and
nonfatal coronary heart disease and con-
gestive heart failure (P  0.01 for all end
points), but not for stroke (P  0.71). In
view of the negative ﬁnding on stroke, we
performed sensitivity analyses in which
we consecutively excluded each of the
four studies; these analyses gave similar
results, so that the negative ﬁnding could
notbeattributedtotheimpactofonepar-
ticular study. In addition, an appropriate
interaction term indicated that the ab-
sence of predictive power of smoking did
not differ among the four studies.
Because of lack of consensus among
studies on the possible risks of stroke
from cigarette smoking, Shinton and
Beevers (8) performed a meta-analysis of
32 studies and found the overall risk of
stroke associated with smoking to be 1.5
(95% CI 1.4–1.6). However, the risk was
lower at older age and was not signiﬁcant
for cerebral hemorrhage, so that the
higher age in our study and the usually
higherprevalenceofcerebralhemorrhage
in hypertension, although not assessed in
our patients, may have contributed to the
negative ﬁnding. The authors (8) also
notedasigniﬁcantdoseresponsebetween
the number of cigarettes smoked and the
relative risk of stroke. It is of note that the
prevalence of smoking was only 13.7% in
our hypertensive study population, and it
is possible that smokers were in general
lighter smokers in view of the advice to
hypertensive patients to reduce and quit
smoking; in fact, 18.5% of the study pop-
ulation were past smokers. Whereas
smoking is usually considered a risk fac-
tor for stroke in population-based studies
(9),therelativeriskofsmokingappearsto
be lower for stroke than for coronary
heart disease (10). Results are less consis-
tent in hypertension; for example, smok-
ing was a signiﬁcant risk factor for
coronary heart disease but not for stroke
in the Medical Research Council trial in
older hypertensive subjects (11), whereas
smoking contributed signiﬁcantly to the
incidence of the two outcomes in the
MedicalResearchCounciltrialofmildhy-
pertension (12).
Finally, we tested the interaction be-
tween smoking and diabetes and ob-
served that the relative risk of smoking
was not greater in diabetic subjects than
in nondiabetic subjects (P  0.6). In ad-
dition, interaction terms between smok-
ing and 24-h systolic blood pressure, age,
sex, total cholesterol, and antihyperten-
sive treatment, respectively, were not sig-
niﬁcant within our study population.
SMOKING AND DIABETES —T o
ﬁnd out about the effect of smoking on
mortality and cause-speciﬁc cardiovascu-
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the effects of smoking and diabetes, we
conducted a literature search with the
PubMed computerized database for rele-
vant studies and examined the reference
lists of the original articles and of reviews
on the topic. Selection criteria to be in-
cluded in this review were as follows:
studiesonsubjectswithtype2diabetesor
with undeﬁned diabetes (assuming a ma-
jority of patients with type 2 diabetes),
with or without inclusion of nondiabetic
subjects, which assessed the relative risk
of smoking, taking into account age, sex,
and other relevant covariates in unequiv-
ocal multivariable analyses. The studies
includetheFirstNationalHealthandNu-
trition Examination Survey (13), a large
case-controlstudy(14),theWorldHealth
Organization Multinational Study of Vas-
cular Disease in Diabetes (15,16), the
U.K. Prospective Diabetes Study (UK-
PDS) (17–19), the Nurses’ Health Study
Cohort (20,21), and the Swedish Na-
tional Diabetes Registry (22). Past smok-
ing was usually not a risk factor in these
studies (13–15,21), with few exceptions
(20), but the results showed that current
smoking is a signiﬁcant and independent
risk factor for all-cause mortality (13,20),
coronary heart disease mortality (13,14),
and cardiovascular disease mortality
(16,20) and for fatal and nonfatal coro-
nary heart disease (15,17,18,21) and ag-
gregates of cardiovascular disease
(21,22). The adjusted relative risks
rangedfrom1.5to2.0.IntheUKPDS
(18), the risk of smoking at diagnosis of
diabetes amounted to 1.55 (95% CI
1.08–2.01) for stroke. However, in one
study, the risk of smoking was not signif-
icant for cerebrovascular disease (15) and
in the Nurses’ Health Study, the relative
riskforstrokeappearedtobelessthanthe
risk for coronary heart disease, as illus-
trated in Table 3 (21).
Finally, we looked for articles that
compared the adjusted relative risks of
smoking in diabetic and nondiabetic sub-
jects and/or reported interaction terms
between smoking and diabetes. Ford and
DeStefano (13) reported that the relative
risk for all-cause mortality of current
smokers versus never-smokers amounted
to 1.60 (95% CI 1.34–1.90) in diabetic
subjects and to 1.79 (1.10–2.91) in non-
diabetic subjects. The interaction term
between smoking and diabetes was not
signiﬁcant, and this was also the case for
coronary heart disease. Similarly,
DeStefanoetal.(14)reportedthattherel-
ative risk for coronary heart disease mor-
tality was 1.8 (1.3–2.6) in older diabetic
patients and 2.2 (1.8–2.5) in older non-
diabetic patients (P for interaction 
0.45), and the risk of smoking was even
less in younger diabetic subjects than in
control subjects (P  0.001). In the
Nurses’ Health Study, the test for interac-
tionbetweendiabetesstatusandsmoking
categories (i.e., never-smokers, past
smokers, light and heavy smokers) was
notsigniﬁcantforall-causemortality(P
0.83) (20) and the relative risk for fatal
and nonfatal coronary heart disease of
current smoking versus never smoking
was2.65(2.06–3.40)fordiabeticwomen
and 5.13 (4.53–5.80) for nondiabetic
subjects (21).
CONCLUSIONS — Smoking is a risk
factor for mortality and coronary heart
disease in hypertension and in diabetes.
The risk for stroke is less consistent in
hypertension and appears to be smaller
than that of CHD in diabetes. Finally,
there is no evidence that the relative risk
of smoking is greater in diabetic subjects
than in nondiabetic subjects. However,
because diabetes is a risk factor for mor-
bidity and mortality, the absolute risk of
Table 1—Multivariable Cox regression analysis for all-cause, cardiovascular, and noncar-
diovascular mortality in 3,468 hypertensive patients
All-cause Cardiovascular Noncardiovascular
Number of events 324 145 179
Smoking 1.76 (1.29–2.39)* 1.89 (1.19–3.01)† 1.68 (1.12–2.52)†
24-h systolic blood pressure 1.35 (1.21–1.51)* 1.44 (1.22–1.71)* 1.28 (1.10–1.50)†
Diabetes 1.87 (1.38–2.55)* 1.69 (1.06–2.69)‡ 2.03 (1.35–3.06)*
Age 1.09 (1.08–1.11)* 1.10 (1.08–1.12)* 1.09 (1.07–1.11)*
Male sex 1.93 (1.52–2.46)* 1.27 (0.88–1.82)
NS 2.70 (1.95–3.75)*
Data are hazard ratios and 95% CIs associated with smoking and diabetes (coded as 1 if yes and 0 if no), 1
SD higher blood pressure, 1 year of age, and male sex (men  1 and women  0); total cholesterol,
antihypertensive treatment, and BMI are not signiﬁcant. *P  0.001; †P  0.01; ‡P  0.05.
Table2—MultivariableCoxregressionanalysisforfatalandnonfatalcoronaryheartdisease,
congestive heart failure, and stroke in 3,468 patients with hypertension
Coronary heart
disease
Congestive heart
failure Stroke
Number of events 129 99 113
Smoking 1.87 (1.20–2.91)† 2.14 (1.22–3.76)† 0.89 (0.49–1.62)
NS
24-h systolic blood pressure 1.44 (1.21–1.71)* 1.45 (1.19–1.78)* 1.73 (1.45–2.06)*
Diabetes 1.15 (0.64–2.04)
NS 2.05 (1.19–3.53)† 2.19 (1.34–3.57)†
Cholesterol 1.20 (1.07–1.35)† 1.05 (0.86–1.26)
NS 1.07 (0.91–1.27)
NS
Age 1.07 (1.05–1.09)* 1.11 (1.08–1.14)* 1.07 (1.05–1.09)*
Male sex 2.70 (1.85–3.94)* 1.32 (0.84–2.07)
NS 2.03 (1.36–3.02)*
Data are hazard ratios and 95% CIs associated with smoking and diabetes (coded as 1 if yes and 0 if no), 1
SD higher blood pressure or total cholesterol level, 1 year of age, and male sex (men  1 and women  0);
antihypertensive treatment and BMI are not signiﬁcant. *P  0.001; †P  0.01;
NSP  0.05.
Table 3—Risk of smoking for coronary heart disease and stroke in the Nurses’ Health Study
Coronary heart
disease* Stroke
Never smokers 1.00 1.00
Past smokers 1.21 (0.97–1.51) 0.69 (0.48–1.00)
Current smokers
1–14 cigarettes/day 1.66 (1.10–2.52) 1.04 (0.50–2.17)
15 cigarettes/day 2.68 (2.07–3.48) 1.84 (1.21–2.81)
P for trend 0.001 0.004
*Coronary heart disease includes fatal CHD and non-fatal myocardial infarction. Data are relative risks vs.
never smokers, adjusted for age, period, alcohol consumption, duration of diabetes, postmenopausal hor-
mone use, diabetes medication use, BMI, family history of myocardial infarction, physical activity, high
cholesterol, and high blood pressure. Adapted from Al-Delaimy et al. (21).
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